)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
ZyVersa Therapeutics
ZyVersa Therapeutics (ZVSA) investor relations material
ZyVersa Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
Clinical-stage biopharma focused on renal and inflammatory diseases with two main drug platforms: VAR 200 (renal) and IC 100 (inflammatory).
No products approved or revenue generated; all resources devoted to R&D and organizational activities.
Lead renal candidate VAR 200 targets FSGS, with Phase 2a trial planned for Q2-2026; IC 100 is in preclinical stage targeting cardiometabolic conditions.
Company delisted from Nasdaq in October 2025, now trades on OTCQB under ZVSA.
Financial highlights
Net loss for 2025 was $25.0 million, up from $9.4 million in 2024, driven by an $18.6 million impairment charge.
Research and development expenses decreased to $1.1 million in 2025 from $1.8 million in 2024.
General and administrative expenses fell to $5.7 million in 2025 from $7.4 million in 2024.
Cash at year-end 2025 was $0.1 million, with a working capital deficit of $12.4 million.
Accumulated deficit reached $137.6 million as of December 31, 2025.
Outlook and guidance
Cash on hand only sufficient for month-to-month operations; additional financing required to continue development.
Plans to raise capital through equity, debt, or strategic partnerships; no assurance of success.
Anticipates continued operating losses and negative cash flows for the foreseeable future.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ZyVersa Therapeutics
- All four shareholder proposals were approved, with board and management updates provided.ZVSA
AGM 202418 Jan 2026 - IC100 and VAR-200 advance toward key clinical milestones, targeting obesity and kidney disease.ZVSALife Sciences Investor Forum13 Jan 2026
- Biopharma seeks up to $100M via flexible securities shelf amid pipeline progress and going concern risk.ZVSARegistration Filing16 Dec 2025
- Biopharma registers 1.6M shares for resale; faces major funding needs and going concern risk.ZVSARegistration Filing16 Dec 2025
- Registering 478,600 shares for resale, company faces urgent funding needs and going concern risks.ZVSARegistration Filing16 Dec 2025
- Registering 4.2M shares for resale tied to warrants, with major funding needs and early-stage pipeline.ZVSARegistration Filing16 Dec 2025
- Annual meeting covers director election, auditor, equity plan, and warrant-related stock issuance.ZVSAProxy Filing2 Dec 2025
- Shareholders will vote on director elections, auditor ratification, equity plan, and major warrant issuances.ZVSAProxy Filing2 Dec 2025
- Shareholders will vote on director elections, auditor, equity plan, and major share issuances.ZVSAProxy Filing2 Dec 2025
Next ZyVersa Therapeutics earnings date
Q1 202611 May, 2026
ZyVersa Therapeutics
Next ZyVersa Therapeutics earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage